Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track WVE with free AI briefings, catalyst countdowns, and dilution alerts.

WVE · Wave Life Sciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$431M Cash on Hand
22.7mo Cash Runway
Follow WVE by email Get an email when WVE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about WVE, unsubscribe in one click. Privacy

📣 What WVE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
WVE-210201 Duchenne Muscular Dystrophy Phase 2/3 · NCT03907072 Terminated
SAD: 30mg WVE-003 Huntington Disease Phase 1/2 · NCT05032196 Completed
WVE-004 ALS Phase 1/2 · NCT04931862 Terminated
WVE-006 Alpha-1 Antitrypsin Deficiency Phase 1/2 · NCT06405633 Recruiting
WVE-007 Overweight and Obesity Phase 1/2 · NCT06842186 Recruiting
WVE-120101 Huntington's Disease Phase 1/2 · NCT03225833 Terminated
WVE-120102 Huntington's Disease Phase 1/2 · NCT03225846 Terminated
WVE-N531 Duchenne Muscular Dystrophy Phase 1/2 · NCT04906460 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

WVE holds $431M in cash and short-term investments (as of Sep 30, 2026) and burns about $56.9M/quarter from operations, an estimated runway of 22.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 25 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when WVE files for a raise →

👥 Who Owns WVE

Insiders 28.6% Institutions (316 holders) 71.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +140,200 options
Insider 26,975,505 13.68% 2026-10-05
GSK plc
10% owner
Insider 18,245,691 9.25% 2025-12-11
Ken Takanashi
Director · +140,200 options
Insider 9,637,187 4.89% 2026-10-05
Chandra Vargeese
Chief Technology Officer, Head of Platfo · +273,750 options
Insider 408,246 0.21% 2026-02-05
Gregory L. Verdine
Director · +64,000 options
Insider 275,917 0.14% 2026-10-05
Paul Bolno
President and CEO, Director · +1.00M options
Insider 275,520 0.14% 2026-02-05
Kyle Moran
Chief Financial Officer · +571,450 options
Insider 134,385 0.07% 2026-02-05
Erik Ingelsson
Chief Scientific Officer
Insider 87,864 0.04% 2026-04-09
Chris Francis
SVP, Corporate Development, Head of Emer · +436,875 options
Insider 61,867 0.03% 2026-02-26
Heidi L Wagner
Director · +64,000 options
Insider 55,630 0.03% 2026-10-05
Christopher I Wright
Chief Medical Officer
Insider 45,625 0.02% 2026-04-09
Mark Corrigan
Director · +140,200 options
Insider 39,515 0.02% 2026-10-05

Share count 197,228,968 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full WVE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for WVE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.